Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market

The prostate cancer drugs market consists of sales of various drugs used for the prevention and treatment of prostate cancer. Prostate cancer is one of the most common types of cancer caused due to uncontrollable development of cells in the prostate gland in men that produces the seminal fluid that nourishes and transports sperm. Some of the possible treatments for prostate cancer include hormonal therapy, chemotherapy, immunotherapy and targeted therapy. The different types of prostate cancer drugs are hormone sensitive prostate cancer and hormone refractory prostate cancer. Hormone-refractory prostate cancer (HRPC) is a kind of prostate cancer that no longer responds to hormone therapy, even newer treatments. The different types of therapies include hormonal therapy, chemotherapy, immunotherapy, targeted therapy and involves various sectors such as hospitals, clinics, others. The global prostate cancer drugs market size is expected to grow from $16.09 billion in 2021 to $17.64 billion in 2022 at a compound annual growth rate (CAGR) of 9.6%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global prostate cancer drug market is expected to reach $23.95 billion in 2026 at a CAGR of 8.0%. The increasing male geriatric population is a major driver for the prostate cancer drugs market. Prostate cancer is one of the most common types of cancer in men aged above 60. According to the United Nations (UN), there were around 703 million people aged 65 or above globally, accounting for 13% of the global population in 2019. The American Cancer Society's statistics for prostate cancer in the USA states that about 6 prostate cancer cases in 10 are diagnosed in men aged 65 or above, and it is rare for men aged less than 40. Recurrent/non-responsive prostate cancer is major restraint for the growth of the prostate cancer drugs market. This is because recurrent/non-responsive prostate cancer cells lead to recurrence or spread of the cancer after an initial treatment. Prostate cancer can recur locally in the tissue next to the prostate, the surrounding lymph nodes in the pelvis or lymph nodes outside this area, tissues next to the prostate (such as the muscles that help control urination, the rectum, or the wall of the pelvis). The cancer can also travel through the bloodstream and recur in bones or other organs. According to the American Society of Clinical Oncology (ASCO), around 50% to 95% of men in the US with high-risk prostate cancer experience recurrence after localized treatment. The use of combination therapy to treat prostate cancer is an emerging trend in the market. This is mainly because in some cases of prostate cancer, monotherapy has not been effective for the patients. In this regard, companies in the prostate cancer drugs market are investing more in combination therapy for the treatment of prostate cancer. For example, Pfizer announced the results of its Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC), which show that the use of XTANDI (enzalutamide) in combination with androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71% compared to using ADT alone. Similarly, other combination therapies such as a combination of radiation therapy and androgen deprivation therapy for men with recurrent prostate cancer, and using chemotherapy drug docetaxel (Taxotere) along with ADT are also being used to treat prostate cancer. The prostate cancer drugs market in the USA is regulated by the FDA which is responsible for approval of new drugs and lays down regulations related to treatment of prostate cancer. For instance, the FDA approved Erleada (apalutamide) for the treatment of prostate cancer that has not spread (non-metastatic), but continues to grow despite treatment with hormone therapy (castration-resistant). This was the first case of FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, and more such approvals are expected to follow in the future. Hence, the regulatory scenario related to prostate cancer drugs will encourage more drug manufacturers to enter the market. In June 2021, Bayer, a Germany based pharmaceutics company acquired Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc for an undisclosed amount. With this acquired Bayer will gain exclusive access to a specialized alpha radionuclide investigational drug built on actinium-225 and a small molecule aimed against prostate-specific membrane antigen. PSMA Therapeutics Inc. is a US-based company that specializes in prostate-specific membrane antigen research and Noria Therapeutics Inc. is a radiotherapy firm focused on creating alpha-emitting radiopharmaceuticals for targeted therapeutic and imaging applications in oncology. Major players in the prostate cancer drugs market are Astellas Inc., AstraZeneca plc, Johnson & Johnson, Sanofi S.A, Bayer AG, Roche, Abbott, Pfizer, Norvaris and F. Hoffmann-La Roche AG. North America is the largest region in the prostate cancer drugs market in 2021. The Middle East is expected to be the fastest growing region in the global prostate cancer drug market during the forecast period. The regions covered in the global prostate cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the prostate cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global prostate cancer drugs market is segmented - 1) By Type: Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer 2) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy 3) By End-User: Hospitals, Clinics, Others

The tumor ablation therapy devices market consists of sales of tumor ablation devices and related services that are used in hospitals and oncology clinics. Tumor ablation is the technique used to extract the tumors using a needle, to insert them in the tumor organ using imaging techniques. The main technologies in the tumor ablation therapy devices are radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, and others. Irreversible electroporation (IRE) in tumor ablation therapy is a new tissue ablation method in which micro to millisecond electrical pulses are supplied to undesirable tissue to produce cell necrosis by irreversible cell membrane permeabilization. The treatments included are surgical, laparoscopic, and percutaneous that are used in various applications such as kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, and others. The various end-users of tumor ablation therapy devices are hospitals, oncology clinics, and others. The global tumor ablation therapy devices market size is expected to grow from $0.49 billion in 2021 to $0.56 billion in 2022 at a compound annual growth rate (CAGR) of 14.1%. The global tumor ablation therapy device market size is expected to grow to $0.97 billion in 2026 at a CAGR of 15%. The increasing prevalence of cancer is a key factor driving the growth of the tumor ablation therapy devices market. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. Tumor ablation is a minimally invasive procedure widely used in the treatment of lung, liver, kidney, and bone tumors. For instance, in 2020, according to the American Institute of cancer research, there were an estimated 18.1 million cancer cases around the world. It was estimated that 9.3 million cases were in men and 8.8 million in women. Among them, lung and breast cancers are the most common cancers in the world, and about 12.5% and 12.2% of the new cases are diagnosed in 2020. The procedure is an effective method for patients who have failed chemotherapy or radiotherapy, thereby supporting the growth of the tumor ablation therapy devices market. Product recalls of tumor ablation devices due to technical issues are expected to hinder the growth of the tumor ablation therapy devices market. The companies are retrieving their products from the market due to safety concerns. For instance, Covidien Emprint Long Percutaneous Antenna with Thermosphere Technology, a tumor ablation device from Medtronic had recalled its devices due to the disengagement of ceramic trocar tip of the Emprint ablation from the needle shaft post-ablation. Similarly, in June 2018, Accurian RF Ablation by Medtronic Sofamor Danek USA Inc was recalled due to the difficulty in insertion. The product recalls caused a financial burden on the companies hindering the tumor ablation therapy devices market. Major companies operating in the tumor ablation therapy devices are focusing on technology advancements for shorter procedures, increased safety, lower exposure to radiation, faster learning curves, and improved outcomes J&J medicals have released a microwave ablation system called NEUWAVE, which is the first minimally invasive device to put electrodes into cancer cells and thereby increase the temperature around them for burning the cancer cells. In June 2020, Boston Scientific has launched a technology called DirectSense technology, a tool used for monitoring the effect of radiofrequency (RF) now for cardiac procedures, which may be further employed for tumors. In June 2019, Varian Medical Systems acquired Endocare for an undisclosed amount. This acquisition will help Varian Medical Systems strengthen its portfolio by adding cryoablation and microwave ablation therapies and embolic beads to its cancer care solutions portfolio. Endocare is a leading provider of hardware and software solutions supporting cryoablation and microwave ablation. Major players in the tumor ablation therapy devices market are Galil Medical Inc, Misonix Inc, HealthTronics, Angiodynamics, Boston Scientific Corporation, Medtronic Plc, EDAP TMS S.A, Neuwave Medical Inc, BVM Medical Limited, and Erbe Elektromedizin GmbH. North America was the largest region in the tumor ablation therapy devices market in 2021. Asia Pacific was the second largest region in the global tumor ablation therapy device market. The regions covered in the global tumor ablation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the tumor ablation therapy devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global tumor ablation therapy devices market is segmented - 1) By Technology: Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation, Others 2) By Treatment: Surgical, Laparoscopic, Percutaneous 3) By End-User: Hospitals, Oncology Clinics, Others 4) By Application: Kidney Cancer, Liver Cancer, Breast Cancer, Lung Cancer, Prostate Cancer, Others

The radiotherapy devices market consists of sales of radiotherapy devices and related services by entities (organizations, sole traders, and partnerships) that manufacture radiotherapy devices. Radiotherapy devices are used in cancer treatment by using high doses of radiation to kill cancer cells and shrink tumors. The main product type of radiotherapy devices is external beam radiation therapy devices, linear accelerator devices, and proton therapy devices. A medical linear accelerator (LINAC) is a radiotherapy device that is generally utilized for external beam radiation treatments for patients with cancer. It supplies high-energy x-rays or electrons to the region of the patient's tumor. The applications are skin cancer, breast cancer, prostate cancer, cervical cancer, lung cancer, and others. These are used in hospitals, ambulatory surgical centers, and oncological treatment centers. The global radiotherapy devices market size is expected to grow from $4.76 billion in 2021 to $5.21 billion in 2022 at a compound annual growth rate (CAGR) of 9.3%. The global radiotherapy device market size is expected to grow to $7.47 billion in 2026 at a CAGR of 9.5%. Technological advancement is anticipated to drive the demand for the radiotherapy devices market. The advancement in technology is helping to develop low-cost, more effective and efficient, and user-friendly products with precise and improved radiation doses for increased performance in targeting tumors. The advancement from 2D radiotherapy devices to 3D with real-time imaging enabled high conformity of radiation to improve tumor control. For instance, in June 2020, Accuray Incorporated, a US-based radiation oncology company launched CyberKnife S7 System, a radiotherapy device combining advanced precision, real-time artificial intelligence, and speed motion tracking and synchronization treatment delivery for stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatments. Therefore, the launch of advanced devices is likely to propel the revenues for the radiotherapy devices market shortly. The high cost of radiotherapy is projected to limit the growth of the radiotherapy devices market as it uses complex machines and involves the services of skilled health care providers. The specific expense of radiation treatment relies upon the expense of medicinal services such as place of patient residence, type of radiation treatment, and the number of medicines required. For example, Proton Therapy is a high-cost therapy that is usually performed in metropolitical cities or at major academic centers. The treatment duration is eight weeks, which leads to huge expenditure on treatment and relocation. According to the report of the National Cancer Institutes, approximately $150.8 billion were spent nationally for cancer care in 2018 in America. The high costs of cancer treatment are especially difficult to overcome among the poor or the uninsured or underinsured population. Therefore, the high cost associated with radiotherapy procedures is expected to restrain the growth of the market. Artificial Intelligence (AI) is a leading trend in the radiotherapy devices market and is gaining significant popularity in the market. The incorporation of AI innovation in disease care is expected to improve the exactness and speed of analysis, help clinical dynamics, and lead to better results. For instance, in September 2019, Varian Medical Systems, a US-based manufacturer of radiation oncology medical devices, launched Ethos artificial intelligence radiotherapy device. The traditional treatment arranging process takes days to make an improved radiation treatment conveyance plan; however, the new AI advancements are helping to speed up this procedure. AI is also expected to include deep learning applications in treatment planning, clinical decision support, automated image-guided adaptive radiation therapy, and genomic/radio-biologic data mining, thus supporting the growth of the market. In August 2020, Siemens Healthineers, a Germany-based medical technology company, announced its decision to acquire Varian Medical Systems Inc., for $16.4 billion. The deal is expected to expand Siemens Healthineer's definitive objective of overarching and comprehensive oncology portfolio, including Varian's linear accelerators, radiosurgery devices, and proton therapy suites to Siemens' imaging hardware, laboratory diagnostics, and hospital consulting services. Varian Medical Systems Inc. is a US-based radiation oncology treatments and software company. Major players in the radiotherapy devices market are Varian Medical Systems, Elekta AB, Accuray Inc, C.R.Bard Inc, IBA Ion Beam Applications SA, Koninklijke Philips N.V, Siemens AG, Eckert & Ziegler Bebig, IsoRay Inc, and GE Healthcare. North America was the largest region in the radiotherapy devices market in 2021. Asia Pacific was the second largest region in the global radiotherapy devices market. The regions covered in the global radiotherapy devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the radiotherapy devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global radiotherapy devices market is segmented - 1) By Product Type: External Beam Radiation Therapy Devices, Linear Accelerator Devices, Proton Therapy Devices 2) By Application: Skin Cancer, Breast Cancer, Prostate Cancer, Cervical Cancer, Lung Cancer, Others 3) By End-User: Hospitals, Ambulatory Surgical Centers, Oncological Treatment Centers

The urology medical lasers market consists of sales of urology medical lasers and related services by entities (organizations, sole traders, and partnerships) that manufacture urology medical lasers. Medical lasers are a non-invasive and efficient source of light used for tissue treatment that provides fast healing without discoloration or scarring. Urology medical lasers are used in the treatment of medical conditions related to the urinary system such as urinary stones, benign prostatic hyperplasia (BPH), bladder or prostate cancer, and traumatic injuries. The main types of urology medical lasers are the holmium laser system, diode laser system, thulium laser system, and others. The holmium laser system is the process of removing stones in the bladder, kidneys, ureters, or urethra using lasers. The applications involved are benign prostatic hyperplasia, urolithiasis, non-muscle-invasive bladder cancer, and others. The end-users involved are hospitals, clinics, and others. The global urology medical lasers market size is expected to grow from $0.77 billion in 2021 to $0.82 billion in 2022 at a compound annual growth rate (CAGR) of 6.6%. The global urology medical laser market is expected to grow to $1.04 billion in 2026 at a CAGR of 6.1%. Rising cases of urological disorders contribute to the demand for the urology medical lasers market. Growing urological cases including bladder cancer and prostate diseases among others are boosting the demand for minimally invasive surgeries and related devices. According to the American Institute for Cancer Research’s statistics on bladder statistics, bladder cancer is the sixth most common cancer in men and the 17th most common cancer in women. The surge in urological diseases and conditions increases the demand for urological surgeries and supports the growth of the urology medical lasers market. Major players operating in the market are continuously focusing on developing new products incorporating advanced technology to meet the requirement of medical professionals. For instance, in June 2020, Olympus Corporation, a Japanese manufacturer of innovative medical and surgical products, launched the Soltive SuperPulsed Thulium Fiber Laser System designed for stone lithotripsy and soft tissue applications in urology. The SuperPulsed thulium fiber laser dust stones into very fine particles faster than other laser systems. In April 2019, Olympus Corporation, a Japan-based manufacturer of innovative technology solutions for medical and surgical procedures, acquired Lithotripsy system design and production technology from Cybersonics, Inc. for an undisclosed amount. The acquisition is expected to help Olympus Corporation to expand manufacturing and enhance treatment for stone disease and enable the company to improve clinical outcomes, reduce costs, and enhance the quality of life of patients. Cybersonics, Inc. is a USA-based company engaged in designing and developing medical devices that utilize ultrasonic energy. The medical devices developed by the company include high-power ultrasonic systems used in the field of neurosurgery, urology, and peripheral vascular surgery. Major players in the urology medical lasers market are Olympus Corporation, Ethicon Inc, Stryker Corporation, Boston Scientific Corporation, Richard Wolf GmbH, Cook Medical Incorporated, Karl Storz SE & Co. KG, Lumenis Ltd, Becton Dickinson and Company, and OmniGuide Holdings Inc. North America was the largest region in the urology medical lasers market in 2021. Asia Pacific was the second largest region in the global urology lasers market. The regions covered in the global urology medical lasers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the urology medical lasers market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The global urology medical lasers market is segmented - 1) By Laser Type: Holmium Laser System, Diode Laser System, Thulium Laser System, Others 2) By Application: Benign Prostatic Hyperplasia (BPH), Urolithiasis, Non-Muscle-Invasive Bladder Cancer (NMIBC), Others 3) By End-User: Hospital, Clinic, Others

The nephrology and urology devices market consists of sales of nephrology and urology devices and related services by entities (organizations, sole traders, and partnerships) that produce nephrology and urology devices used in the diagnosis and treatment of kidney and genitourinary diseases. The main types of nephrology and urology devices are dialysis devices and equipment, urinary stone treatment devices and equipment, urinary incontinence and pelvic organ prolapse devices and equipment, benign prostatic hyperplasia (BPH) treatment devices and equipment, and endoscopy devices, and equipment. Dialysis devices and equipment is a machine used in dialysis that filters a patient's blood to remove excess water and waste products when the kidneys are damaged, dysfunctional, or missing. The dialysis machine itself is an artificial kidney. The type of expenditure is public and private. The products used are instruments/equipment and disposables. The various end-users are hospitals and clinics, diagnostic laboratories, and others. The global nephrology and urology devices market size is expected to grow from $15.85 billion in 2021 to $17.27 billion in 2022 at a compound annual growth rate (CAGR) of 9.0%. The global nephrology and urology device market size is expected to grow to $23.07 billion in 2026 at a CAGR of 7.5%. The increase in the patient pool due to the rising geriatric population globally contributed significantly to the growth of the nephrology and urology devices market during the historic period. According to the Population Reference Bureau, the share of the population over the age of 65 in the global population increased to 9% in 2019. The global population aged 65 years or over was 703 million in 2019. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. These factors increased the demand for these products and drove the market during the historic period. The nephrology and urology devices market was limited by the shortage of skilled workforce in most developed and developing countries, during the historic period. Equipment fabrication and integration require specialized skillsets relating to life sciences, pharmaceuticals, electronics, and software. These skillsets are available to a limited number of organizations, most of which are located in the USA and Europe. This shortage of skilled labor was a significant deterrent to the growth of the market during the historic period. The nephrology and urology market is witnessing a rise in new product launches. Due to the high competition in the market, many companies are investing in advanced technologies to widen product portfolios and increase their share in the market. For instance, in March 2020, Medi-Tate an Israel-based medical device company has received authorization for iTind system that is used to implant and remove nitinol devices during bladder neck remodeling. Researchers at Washington University in St. Louis, the University of Illinois at Urbana-Champaign, and Northwestern University together developed a wireless implant to control overactive bladder using LED lights. Major companies in the nephrology and urology devices market include Baxter International Inc, Fresenius Medical Care AG & Co KGaA, Cook Group Incorporated, B. Braun Group, C. R. and Bard Inc. North America was the largest region in the global nephrology and urology devices market in 2021. Asia Pacific was the second largest region in the global nephrology and urology devices market. The regions covered in the global nephrology and urology devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the nephrology and urology devices market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The global nephrology and urology devices market is segmented - 1) By Type: Dialysis Devices and Equipment, Urinary Stone Treatment Devices and Equipment, Urinary Incontinence and Pelvic Organ Prolapse Devices and Equipment, Benign Prostatic Hyperplasia (BPH) Treatment Devices and Equipment, Endoscopy Devices and Equipment 2) By End-User: Hospitals and Clinics, Diagnostic Laboratories, Others 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables

The urinary incontinence and pelvic organ prolapse devices and equipment market consist of sales of urinary incontinence and pelvic organ prolapse devices and equipment and related services. Urinary incontinence (UI), also known as involuntary urination, is defined as an uncontrolled leakage of urine caused due to overactive bladderPelvic organ prolapse (POP) is caused because of the defects in the supporting structures of the vagina. Depending on the size and location of the defect, the functions of the organs contained within the female pelvis can alter their normal functioning. The main types in the urinary incontinence and pelvic organ prolapse devices and equipment are urinary incontinence devices and pelvic organ prolapse devices. Urinary incontinence devices are the devices that are used to treat urinary incontinence. The urinary incontinence devices are artificial urinary sphincters, electrical stimulation devices, urethral slings, and catheters. The pelvic organ prolapse devices are vaginal mesh and vaginal pessary. The incontinence types are stress incontinence, urge incontinence, overflow incontinence, functional incontinence. The various end-user involved are hospitals, clinics, ambulatory surgical centers, and home use. The global urinary incontinence & pelvic organ prolapse devices and equipment market size is expected to grow from $0.38 billion in 2021 to $0.42 billion in 2022 at a compound annual growth rate (CAGR) of 10.3%. The global urinary incontinence and pelvic organ prolapse devices and equipment market size is expected to grow to $0.59 billion in 2026 at a CAGR of 8.8%. The increased prevalence rate for Pelvic organ prolapse (POP) as well as for urinary incontinence (UI) disorders has been driving the growth of urinary incontinence and pelvic organ prolapse devices and equipment market. The increasing prevalence rate has led manufacturers towards developing more accurate and efficient devices for the treatment of these disorders. The POP affects women of all ages, however, old age women are more prone to POP disorders. According to US FDA reports, the number of women who have POP is expected to increase by 46%, to 4.9 million, by 2050. According to a report published by the American Urological Association (AUA/SUFU), the prevalence of stress urinary incontinence (SUI) in women was reported to be as high as 49%. The prevalence rate of stress urinary incontinence is high in the poor nutritional status group, as it results in weakness of pelvic supports. This high prevalence rate is driving the demand for medical equipment for urinary incontinence and pelvic organ prolapse. The urinary incontinence and pelvic organ prolapse devices and equipment market are being restrained by rising health issues due to the use of vaginal mesh for the treatment of UI and POP. Regulatory agencies such as FDA and NICE have devised new guidelines for the manufacturers to address these concerns. The vaginal mesh implants generally use a Polypropylene layer over the implants. Such vaginal mesh implants containing Polypropylene have caused severe medical complications in millions of women across the world, therefore, manufacturers are now forced to develop an alternative material, such as polyurethane, which is better suited to be used by women without any health complications for treatment of pelvic organ prolapse and urine incontinence. For instance, on March 8, 2019, C.R. Bard, one of the major players in the urinary incontinence and pelvic organ prolapse devices and equipment industry, announced its exit from the market of manufacturing and sale of vaginal mesh products in all markets worldwide after facing lawsuits from various women campaign groups across the globe. These concerns about the safety of vaginal mesh are resulting in stringent manufacturing regulations and affecting sales, thus restraining the UI and POP devices and equipment market. The urinary incontinence and pelvic organ prolapse devices and equipment industry is characterized by the increased use of several new technologies in recent years. There is a wide range of devices being developed to treat both POP and urinary incontinence. For instance, The Lyrette transurethral SUI system led by Verathon Medical UK Ltd is the only FDA-approved treatment used for the treatment of stress urinary incontinence (SUI) among women. Devices such as Lyrette transurethral SUI system are used for procedures for incontinence. The treatment through Lyretter does not require the use of anesthesia or surgery instead it uses radiofrequency energy to tighten the tissue of the bladder. For the treatment of POP, companies are now focusing on using native tissue prolapse repair procedures instead of the vaginal mesh after the adverse health issues from the usage of vaginal mesh were highlighted. Regulatory bodies, such as the FDA in the US, regulate the manufacturing and safety guidelines for devices and equipment related to urinary incontinence and pelvic organ prolapse disorders. For instance, manufacturers are required to obtain pre-market clearance (510(k)) of the tools specifically for implanting surgical mesh. FDA requires the manufacturers in urinary incontinence and pelvic organ prolapse devices and equipment industry to conduct post-market studies to check the specific safety and effectiveness concerns related to surgical mesh used for the repair of POP. For example, FDA regulations resulted in many companies taking down their product completely from the market and made companies like Coloplast and Acell discontinue marketing of their products- Coloplast's Restorelle DirectFix Posterior and Acell Matristem's Pelvic Floor Repair Matrix respectively. Major players in the urinary incontinence and pelvic organ prolapse devices and equipment market are Boston Scientific Corporation, Coloplast Group, Ethicon US, C. R. Bard Inc., Johnson & Johnson, Teleflex Incorporated, Medtronic plc, Covidien, Cook Medical, and Neomedic. The regions covered in the global urinary incontinence and pelvic organ prolapse devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the global urinary incontinence and pelvic organ prolapse devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global urinary incontinence & pelvic organ prolapse devices and equipment market is segmented - 1) By Type: Urinary Incontinence Devices, Pelvic Organ Prolapse Devices 2) By Urinary Incontinence Device: Artificial Urinary Sphincters, Electrical Stimulation Devices, Urethral Slings, Catheters 3) By Pelvic Organ Prolapse Device: Vaginal Mesh, Vaginal Pessary 4) By Incontinence Type: Stress Incontinence, Urge Incontinence, Overflow Incontinence, Functional Incontinence 5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Home Use

The urinary stone treatment devices (or) equipment market consists of sales of urinary stone treatment devices and related services which are used in the treatment and management of stones formed in the kidneys and urinary tract. Stones are made of minerals in the urine that form crystals and grow into stones. About 85% of the stones are made of calcium, and the remaining portion is composed of various substances including cysteine, uric acid, or struvite. The main products in the urinary stone treatment devices/ equipment are the extracorporeal shock wave lithotripsy devices, holmium laser devices, intracorporeal lithotripsy devices, stone retrieval devices, and ureteral stents. Holmium laser devices use pulsed laser and emit light at 2100 nm to break stones in the urinary tract. The stone types involved are calcium stones, struvite, uric acid, cystine, and drug-induced. The various end-users are hospitals, ambulatory surgery centers, and others. The global urinary stone treatment devices and equipment market size is expected to grow from $2.55 billion in 2021 to $2.79 billion in 2022 at a compound annual growth rate (CAGR) of 9.5%. The global urinary stone treatment devices market size is then expected to grow to $3.8 billion in 2026 at a CAGR of 8.0%. The increasing prevalence of Kidney Stones, especially in the geriatric population is driving the urinary stone treatment devices and equipment market growth. The incidence of urolithiasis is reported to be increasing across the globe. According to a study, about 30% of people around the world are obese and nearly 900 million people are geriatrics which is expected to increase to 1.4 billion by 2030. The incidence of kidney stones is globally increasing with an estimated prevalence ranging up to 15%. According to a Robotic Stone survey, the probability of stone formation in Saudi Arabia is 20.1% and 13% in the USA. Stone diseases or urolithiasis are frequent in the aging population. Asia Pacific is presently home to more than half of the world’s aging population above 60 years and the number is expected to rise to 2.45 billion by 2050. Lack of public awareness and proper knowledge about the problems associated with urinary stone diseases, particularly in under-developed countries acts as a major factor hindering market growth. This lack of proper knowledge becomes a roadblock for the Urinary stone treatment device manufacturers because of many cases being unnoticed/unaddressed which amounts to a decrease in demand for these devices. For instance, according to a study conducted in Saudi Arabia, 44% of the participants had a family member suffering from urinary stone disease and 9.6% had urinary stones themselves, which suggests a high prevalence of the ailment in the country. But there was an incidence of lack of awareness and misconceptions among the people in most parts of that region. Companies in the industry are investing in advanced laser technology and robot-assisted surgeries to treat urolithiasis. Urolithiasis is a disease condition where calculi or stones are formed in the kidney, bladder, and urinary tract of the human body. Urolithiasis open surgeries are increasingly conducted with the help of minimally invasive procedures, advanced lasers, enhanced surgical tools, and robot-assisted devices to reduce hospitalization time, be less invasive and enable a shorter bladder catheterization time. For instance, Boston Scientific Co. is investing by way of an agreement with Lumenis, a company offering minimally-invasive clinical solutions, and holmium laser technology, to use and leverage the benefits of advanced laser technology. In March 2019, regarding a field corrective action sent by Medicines and Healthcare products Regulatory Agency (MRHA), a regulatory body for medical devices of the UK, C.R Bard, a subsidiary of Becton, Dickinson, and Company (BD) removed its Women’s Pelvic Organ Prolapse and Stress Urinary Incontinence Mesh devices from the European market. This initiative of ceasing production and distribution of these devices and removal of these products from hospitals and distribution centers was done to protect patient and user safety from these devices. Major players in the urinary stone treatment devices or equipment market are Boston Scientific, Cook Medical, C.R. Bard, DirexGroup, Dornier MedTech, Bard Medical Division, Richard Wolf, Siemens Healthineers AG, Olympus Corporation, and Karl Storz. The regions covered in the global urinary stone treatment devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the global urinary stone treatment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global urinary stone treatment devices and equipment market is segmented - 1) By Product: Extracorporeal Shock Wave Lithotripsy Devices, Holmium Laser Devices, Intracorporeal Lithotripsy Devices, Stone Retrieval Devices, Ureteral Stents 2) By Stone Type: Calcium Stones, Struvite, Uric Acid, Cystine, Drug-Induced 3) By End-User: Hospitals, Ambulatory Surgery Centers, Others

The genito-urinary drugs market consists of sales of genito-urinary drugs and related services by entities (organizations, sole traders and partnerships) that produce genito-urinary drugs to treat genito- urinary diseases such as urinary tract infections, male reproductive diseases, voiding diseases, female reproductive diseases, glomerular disorders, urinary calculi, cystic kidney disease, Reno vascular diseases, benign prostate diseases, and other related diseases. This industry includes establishments that produce infertility drugs, hormonal contraceptives, erectile dysfunction drugs and hormonal replacement drugs to treat infertility, infections and prevent pregnancy. It also consists of establishments which produce drugs for benign prostatic hypertrophy, drugs for urinary incontinence and overactive bladder, diuretics to treat urinary calculi, glomerular disorders and other urinary disorders. The main types of genito-urinary drugs are hormonal contraceptives, drugs for benign prostatic hypertrophy, drugs for infertility, drugs for erectile dysfunction, drugs for urinary incontinence and overactive bladder, drugs for infections and others, drugs for hormonal replacement therapy and diuretics. Hormonal contraceptives are medications or devices that reduce the likelihood of becoming pregnant. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global genito-urinary drugs market size is expected to grow from $40.40 billion in 2021 to $42.75 billion in 2022 at a compound annual growth rate (CAGR) of 5.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The genito-urinary drugs market is expected to reach $63.83 billion in 2026 at a CAGR of 10.5%. The aging population profile of most countries contributed to the growth of the gastrointestinal drugs market. The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.2 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period. Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies during the historic period. Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs. Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin, which negatively impacted the attractiveness of the genito-urinary drugs industry in the historic period. Pharmaceutical companies are investing in development of new class drugs for treating overactive bladders (OAB). Earlier anti-muscarinic agents have been used for the treatment of OAB. Going forward, the market is expected to be driven by a new class of drug known as beta-3 adrenergic agonists that has been increasingly used to treat OAB. Beta-3 adrenergic agonists are drugs which cause the bladder muscles to relax without causing side effects such as dry mouth. For instance, In December 2019, GEMTESA's new drug application (NDA) was submitted to the US Food and Drug Administration (FDA), and it was accepted for review in March 2020. GEMTESA ® is a beta-3 adrenergic agonist used to treat overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency. Major companies in the genito-urinary drugs market include Sanofi S.A, GlaxosmithKline, AstraZeneca, AbbVie, Reckitt, Benckiser Group plc, Astellas Pharma Inc., Otsuka Holdings Co ltd, Pfizer Inc., Merck KGaA and Daiichi Sankyo Company. North America was the largest region in the genito-urinary market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the genito-urinary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global genito-urinary drugs market is segmented - 1) By Type: Hormonal Contraceptives, Drugs for Benign Prostatic Hypertrophy, Drugs for Infertility, Drugs for Erectile Dysfunction, Drugs for Urinary Incontinence and Overactive Bladder, Drugs for Infections and Others, Drugs for Hormonal Replacement Therapy, Diuretics 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs